clopidogrel and Infections, Coronavirus

clopidogrel has been researched along with Infections, Coronavirus in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	3 (100.00)	2.80

Authors

Authors	Studies
Brüggemann, R; Gietema, H; Jallah, B; Spaetgens, B; Stehouwer, C; Ten Cate, H	1
Forleo, GB; Radovanovic, D; Santus, P; Viecca, M	1
Huang, Z; Lin, Y; Su, H; Wang, N; Zhang, M	1

Trials

1 trial(s) available for clopidogrel and Infections, Coronavirus

Article	Year
Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. Pharmacological research, 2020, Volume: 158 Topics: Aged; Aspirin; Betacoronavirus; Clopidogrel; Compassionate Use Trials; Coronavirus Infections; COVID-19; Female; Fibrin Fibrinogen Degradation Products; Humans; Hypoxia; Male; Middle Aged; Pandemics; Platelet Aggregation Inhibitors; Pneumonia, Viral; Proof of Concept Study; SARS-CoV-2; Thrombophilia; Tirofiban	2020

Article

Year

Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study.

Pharmacological research, 2020, Volume: 158

Topics: Aged; Aspirin; Betacoronavirus; Clopidogrel; Compassionate Use Trials; Coronavirus Infections; COVID-19; Female; Fibrin Fibrinogen Degradation Products; Humans; Hypoxia; Male; Middle Aged; Pandemics; Platelet Aggregation Inhibitors; Pneumonia, Viral; Proof of Concept Study; SARS-CoV-2; Thrombophilia; Tirofiban

2020

Other Studies

2 other study(ies) available for clopidogrel and Infections, Coronavirus

Article	Year
Arterial and venous thromboembolic disease in a patient with COVID-19: A case report. Thrombosis research, 2020, Volume: 191 Topics: Anticoagulants; Cerebral Infarction; Clopidogrel; Computed Tomography Angiography; Coronavirus Infections; COVID-19; Frontal Lobe; Humans; Male; Middle Aged; Nadroparin; Pandemics; Peripheral Arterial Disease; Pneumonia, Viral; Pulmonary Embolism; Recombinant Proteins; Recurrence; Thrombophilia; Tinzaparin; Tissue Plasminogen Activator	2020
Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic. The Journal of international medical research, 2020, Volume: 48, Issue:10 Topics: Aged; Aspirin; Clopidogrel; Coronavirus Infections; COVID-19; Female; Fibrinolysis; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Reperfusion; Pandemics; Percutaneous Coronary Intervention; Pneumonia, Viral; Recombinant Proteins; ST Elevation Myocardial Infarction; Stents; Survival Analysis; Treatment Outcome; Urokinase-Type Plasminogen Activator	2020

Article

Year

Arterial and venous thromboembolic disease in a patient with COVID-19: A case report.

Thrombosis research, 2020, Volume: 191

Topics: Anticoagulants; Cerebral Infarction; Clopidogrel; Computed Tomography Angiography; Coronavirus Infections; COVID-19; Frontal Lobe; Humans; Male; Middle Aged; Nadroparin; Pandemics; Peripheral Arterial Disease; Pneumonia, Viral; Pulmonary Embolism; Recombinant Proteins; Recurrence; Thrombophilia; Tinzaparin; Tissue Plasminogen Activator

2020

Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic.

The Journal of international medical research, 2020, Volume: 48, Issue:10

Topics: Aged; Aspirin; Clopidogrel; Coronavirus Infections; COVID-19; Female; Fibrinolysis; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Reperfusion; Pandemics; Percutaneous Coronary Intervention; Pneumonia, Viral; Recombinant Proteins; ST Elevation Myocardial Infarction; Stents; Survival Analysis; Treatment Outcome; Urokinase-Type Plasminogen Activator

2020